The latest biotech news

advicenne ipo rare disease children drta

News and Trends 6 Dec 2017

Update: French Biotech Closes €27M IPO to be the First to Treat Rare Disease in Children

Update (6/12/2017): Advicenne has raised a total of €27M on Euronext Paris, putting its market cap at €112M. Originally published on 21/11/2017 Advicenne is launching an IPO on Euronext Paris to raise the funds to bring the first treatment for dRTA, a rare disease of the kidneys, to the market. Advicenne, based in Nîmes, France, has officially […]

December 6, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Dec 2017

The Philippines Blocks Sanofi’s Dengue Vaccine for Safety Reasons

Following alarming research about the safety of Sanofi’s dengue vaccine, Dengvaxia, The Philippines has halted its sale, distribution and marketing “to protect the general public.” Before Sanofi Pasteur distributed its dengue vaccine, Dengvaxia, there were some concerns that it would make people sicker. Last year, researchers from top American and British institutions confirmed these suspicions […]

December 5, 2017 - 3 minutesmins - By Evelyn Warner

GeneSight eye gene therapy sight restoration

News and Trends 5 Dec 2017

Update: French Gene Therapy Yields Longer Term Sight Restoration, Eyes Phase III

Update (05/12/2017): GenSight has reported a sustained effect of its treatment GS010, which has now been shown to restore sight in patients for at least 2.5 years after administration. Phase III results for the candidate are expected next year. Originally published 14/06/2017 GenSight has announced Phase I/II data revealing that its gene therapy technology can […]

December 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Dec 2017

Israeli Biotech Gets $30M Backing for its Immune Modulators for Severe Infections

Atox Bio develops immune modulators to save patients with severe infections. An oversubscribed Series F financing will support its lead candidate through a Phase II trial. Atox Bio, which has operations in the US and Israel, develops immune modulators for patients with severe infections. The biotech was established at the Hebrew University of Jerusalem and Yissum. […]

December 4, 2017 - 2 minutesmins - By Alex Dale

hypertension treatment idorsia janssen2 1

News and Trends 4 Dec 2017

Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III

Idorsia will collaborate with Janssen on the development of its hypertension drug, aprocitentan, which could help to prevent future heart attacks and strokes. Idorsia was born out of Actelion’s massive $30B (€27.9B) acquisition by Johnson & Johnson, retaining all of the former biotech’s early-stage assets. The company develops small molecules for a broad range of […]

December 4, 2017 - 3 minutesmins - By Alex Dale

News and Trends 4 Dec 2017

Dutch Bone Marrow Transplant for Blood Cancer could get rid of Donor Matching

Kiadis Pharma starts Phase III trials with ATIR101, a therapy that could make half-matched donors suitable for bone marrow transplant to treat blood cancer. From its Amsterdam headquarters, Kiadis Pharma is developing a technology that could solve one of the biggest problems of bone marrow transplantation: finding a donor match. Currently, a bone marrow transplant is […]

December 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Dec 2017

Novozymes and Danish Pump Producer Set Sail in Pursuit of Clean Water

As part of the company’s HelloScience initiative, Novozymes will combine its enzyme and microbial technology with Grundfos’ water pumps to provide clean water and better sanitation. Novozymes aims to improve industrial performance without harming our planet. Earlier this year, the company set up HelloScience, an online platform bringing together experts in a number of fields […]

December 4, 2017 - 2 minutesmins - By Alex Dale

News and Trends 1 Dec 2017

The Door Opens for Dutch Brain Surgery Device to Enter the Clinic

Polyganics has received €1.2M to complete the development of its dura sealant patch, which will be used to reduce the complications of brain surgery. Polyganics, based in the Groningen Medtech Hub, develops bioresorbable medical devices that aid tissue repair and regeneration. Today, the company has announced that it has received €1.2M from the European Fund for Regional […]

December 1, 2017 - 2 minutesmins - By Alex Dale

News and Trends 30 Nov 2017

Interview: Why Asian CROs are Turning to the European Biotech Market

The demand for contract research organizations (CROs) has been increasing steadily worldwide. With more and more clinical development programs being launched and a heightened demand for pharmaceutical products, companies in the biotechnology, pharmaceutical and medical technology industries are frequently deciding to outsource R&D processes to CROs. To give you an idea in numbers: In 2014, […]

November 30, 2017 - 11 minutesmins - By External Contributor

News and Trends 30 Nov 2017

Qiagen Joins French Biotech to Build the Next Generation of Microbiome Technology

Biomillenia harnesses the power of bacteria to keep the body healthy. The biotech has joined forces with Qiagen to develop microbiome-on-a-chip technology. Scientists around the world believe that the microbiome could hold the key to human health. One company in this area, Biomillenia, develops microbial strains from previously unculturable microbiomes to unlock its full potential. The company has now […]

November 30, 2017 - 3 minutesmins - By Alex Dale

dystrophic epidermolysis bullosa proqr rna therapy

News and Trends 30 Nov 2017

RNA Therapy for Rare Skin Disease Gets Orphan Status

The EMA has granted orphan drug designation to ProQR’s QR-313, a possible first disease-modifying treatment for the rare disease dystrophic epidermolysis bullosa. Dystrophic epidermolysis bullosa (DEB) is a genetic disease that causes the skin to easily blister, severely affecting the quality of life of patients since a very early age. Current treatment is limited to […]

November 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Nov 2017

What Exactly Happens in the Cells of People with Down’s Syndrome?

Researchers in Switzerland have taken a closer look at the cells of Down’s syndrome patients, with widespread changes in protein expression observed. Down’s syndrome, or trisomy 21, is the most common genetic disease, characterized by facial dysmorphism, learning disabilities, poor muscle tone and heart problems. Research carried out at the University of Geneva and ETH […]

November 29, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Update: French Biotech Closes €27M IPO to be the First to Treat Rare Disease in Children

The Philippines Blocks Sanofi’s Dengue Vaccine for Safety Reasons

Update: French Gene Therapy Yields Longer Term Sight Restoration, Eyes Phase III

Israeli Biotech Gets $30M Backing for its Immune Modulators for Severe Infections

Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III

Dutch Bone Marrow Transplant for Blood Cancer could get rid of Donor Matching

Novozymes and Danish Pump Producer Set Sail in Pursuit of Clean Water

The Door Opens for Dutch Brain Surgery Device to Enter the Clinic

Interview: Why Asian CROs are Turning to the European Biotech Market

Qiagen Joins French Biotech to Build the Next Generation of Microbiome Technology

RNA Therapy for Rare Skin Disease Gets Orphan Status

What Exactly Happens in the Cells of People with Down’s Syndrome?

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!